Analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share of ($1.18) for the current quarter, according to Zacks. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($1.17) and the lowest estimate coming in at ($1.18). Atara Biotherapeutics posted earnings per share of ($1.02) in the same quarter last year, which would indicate a negative year-over-year growth rate of 15.7%. The business is scheduled to announce its next earnings results on Thursday, November 8th.
On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.58) per share for the current year, with EPS estimates ranging from ($4.59) to ($4.58). For the next financial year, analysts expect that the firm will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.17).
In related news, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $37.74, for a total transaction of $56,610.00. Following the completion of the sale, the insider now directly owns 33,358 shares in the company, valued at approximately $1,258,930.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 8,800 shares of the company’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $51.74, for a total value of $455,312.00. Following the sale, the chief executive officer now owns 812,613 shares of the company’s stock, valued at $42,044,596.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 169,400 shares of company stock worth $7,301,767. Corporate insiders own 10.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Riverhead Capital Management LLC purchased a new stake in Atara Biotherapeutics in the 1st quarter valued at approximately $100,000. SG Americas Securities LLC purchased a new stake in Atara Biotherapeutics in the 1st quarter valued at approximately $107,000. Great West Life Assurance Co. Can lifted its stake in Atara Biotherapeutics by 100.1% in the 2nd quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 1,655 shares in the last quarter. Bank of Montreal Can purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $180,000. Finally, Highland Private Wealth Management purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $202,000. Hedge funds and other institutional investors own 98.58% of the company’s stock.
Atara Biotherapeutics traded up $0.65, hitting $38.10, during trading hours on Friday, according to MarketBeat. The company’s stock had a trading volume of 229,898 shares, compared to its average volume of 436,390. Atara Biotherapeutics has a 12 month low of $12.65 and a 12 month high of $54.45. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -9.53 and a beta of 2.55.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.